Oraya Therapeutics

An Exciting New Treatment Option

Please check this section frequently for updates on news announcements, industry events, and for our latest media resources.


British and Eire Association of Vitreoretinal Surgeons (BEAVRS)
November 5-6 | Sheffield, United Kingdom

Retina Subspecialty Day (AAO 2015)
November 13-14 | Las Vegas, Nevada USA

American Academy of Ophthalmology (AAO 2015)
November 14-17 | Las Vegas, Nevada USA | Oraya Therapy Stand 2041

Latest Press Releases

Tuesday, October 20, 2015 | Oraya Therapeutics Inc. announced today that the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists have issued a joint opinion on the adjunctive use of radiotherapy with the IRay® Stereotactic Radiotherapy System for neovascular age-related macular degeneration. More >

Tuesday, September 29, 2015 | Oraya Therapeutics Inc. announced today that leading ophthalmologists from three European countries presented patient results following one year after a single treatment with Oraya Therapy for wet age-related macular degeneration… More >

Tuesday, June 16, 2015 | Oraya Therapeutics Inc. and Bridge Design announced today that the Oraya IRay® Radiotherapy System has won the Silver award in the radiological and electromechanical devices category of the 18th Annual Medical Design Excellence Awards (MDEA). More >

Tuesday, May 19, 2015 | Oraya Therapeutics Inc. announced today at the Royal College of Ophthalmologists Annual Congress that U.K. ophthalmologists are the leading adopters of Oraya Therapy for the treatment of wet age-related macular degeneration (AMD), two years after the treatment was introduced in the country. Sheffield Teaching Hospitals NHS Foundation Trust alone has treated more than 150 patients in the year since the service was commissioned, with other National Health Service and private centers in England also increasing their treatment with Oraya Therapy. More >

Tuesday, March 3, 2015 | Oraya Therapeutics announced today that the Oraya IRay® Radiotherapy system has received a CE Mark extension for the treatment of choroidal metastases, a cancer in the eye, originating most commonly from primary sites in the breast or lung. This new indication of use expands upon Oraya’s prior approval for the treatment of wet Age Related Macular Degeneration (AMD) and may offer patients in the United Kingdom, Germany and Switzerland a new treatment option for a vision-threatening condition. More >

Thursday, January 22, 2015 | The AMD Alliance International today led an event at the House of Commons that addressed the current issues the NHS is facing with diagnosing, treating and managing the growing number of ageing people affected by age – related macular degeneration (AMD), the leading cause of blindness in the western world. The event was hosted by Sir David Amess, Member of Parliament for Southend West and sponsored by Oraya Therapeutics, Inc. More >

Wednesday, January 7, 2015 | Carl Zeiss Meditec AG and Oraya Therapeutics, Inc. (Oraya) jointly announced today that the companies have entered into a collaboration agreement under which Carl Zeiss Meditec will provide funding to Oraya over a period of up to two years for the implementation of Oraya’s growth strategy, and in turn receive rights in the company reaching up to a majority stake after two years…More >

Latest News

January 23, 2015 | Eyewire Today
The UK’s Leading Blindness Organizations Come Together at House of Commons to Call for Better Funding, Screening, and Treatment for Macular Degeneration.

Back To Top

The INTREPID Trial of Stereotactic Radiosurgery for Choroidal Neovascularization
in AMD
- Peter K. Kaiser, M.D.
© 2015 All rights reserved. Oraya Therapeutics, Inc. The IRay® is a CE-marked medical device. The IRay is not available for sale in the United States. For additional details, including safety and risk information, please see the ORAYA THERAPY section of this website. Oraya, Oraya Therapy, IRay and I-Guide are either trademarks or registered trademarks of Oraya Therapeutics, Inc. in the United States and other countries.